{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:12Z","timestamp":1792782972486,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the Science and Technology Project of the Sichuan Provincial Administration of Traditional Chinese Medicine","award":["2024MS021"],"award-info":[{"award-number":["2024MS021"]}],"id":[{"id":"https:\/\/ror.org\/03x55t826","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Science and Technology Plan Project of Luzhou City","award":["2023JYJ025"],"award-info":[{"award-number":["2023JYJ025"]}]},{"name":"Innovation Team for Integrated Traditional Chinese and Western Medicine in the Prevention and Treatment of Digestive System Diseases, Self-Established Project by Southwest Medical University","award":["2020-CXTD-01"],"award-info":[{"award-number":["2020-CXTD-01"]}]},{"name":"Southwest Medical University Integrated Traditional Chinese and Western Medicine Special Program","award":["2024ZXYZX17"],"award-info":[{"award-number":["2024ZXYZX17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10620-026-10134-1","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:00:17Z","timestamp":1786539617000},"page":"6064-6099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Potential of Complementary and Alternative Therapies in Improving Diarrhea-Predominant Irritable Bowel Syndrome: Strategies for Long-Term Efficacy"],"prefix":"10.1007","volume":"71","author":[{"given":"Yuqing","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"10134_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","volume":"150","author":"DA Drossman","year":"2016","unstructured":"Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016;150:1257\u20131261.","journal-title":"Gastroenterology"},{"key":"10134_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2468-1253(20)30212-0","volume":"6","author":"I Aziz","year":"2021","unstructured":"Aziz I, Simr\u00e9n M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol 2021;6:139\u2013148.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10134_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","volume":"17","author":"CJ Black","year":"2020","unstructured":"Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020;17:473\u2013486.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10134_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","volume":"10","author":"RM Lovell","year":"2012","unstructured":"Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-721.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10134_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1053\/j.gastro.2019.12.021","volume":"158","author":"OS Palsson","year":"2020","unstructured":"Palsson OS, Whitehead W, T\u00f6rnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology 2020;158:1262-1273.e3.","journal-title":"Gastroenterology"},{"key":"10134_CR6","first-page":"1151","volume":"49","author":"Y Li","year":"2021","unstructured":"Li Y, Yang L, Zhao Z, Li J, Guo R. Interpretation of the \u201c2020 Chinese Expert Consensus on Irritable Bowel Syndrome.\u201d Chin J Clin 2021;49:1151\u20131155.","journal-title":"Chin J Clin"},{"key":"10134_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","volume":"5","author":"P Oka","year":"2020","unstructured":"Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:908\u2013917.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10134_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","volume":"160","author":"AD Sperber","year":"2021","unstructured":"Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 2021;160:99-114.e3.","journal-title":"Gastroenterology"},{"key":"10134_CR9","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1038\/533S101a","volume":"533","author":"M Grayson","year":"2016","unstructured":"Grayson M. Irritable bowel syndrome. Nature 2016;533:S101.","journal-title":"Nature"},{"key":"10134_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/gutjnl-2022-328515","volume":"72","author":"M Camilleri","year":"2023","unstructured":"Camilleri M, Boeckxstaens G. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Gut 2023;72:590\u2013599.","journal-title":"Gut"},{"key":"10134_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","volume":"70","author":"DH Vasant","year":"2021","unstructured":"Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021;70:1214\u20131240.","journal-title":"Gut"},{"key":"10134_CR12","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.3390\/jcm13226948","volume":"13","author":"AJ Papale","year":"2024","unstructured":"Papale AJ, Flattau R, Vithlani N, Mahajan D, Nadella S. A review of pharmacologic and non-pharmacologic therapies in the management of irritable bowel syndrome: current recommendations and evidence. J Clin Med 2024;13:6948.","journal-title":"J Clin Med"},{"key":"10134_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.gtc.2021.03.009","volume":"50","author":"JM Shapiro","year":"2021","unstructured":"Shapiro JM, Deutsch JK. Complementary and alternative medicine therapies for irritable bowel syndrome. Gastroenterol Clin North Am 2021;50:671\u2013688.","journal-title":"Gastroenterol Clin North Am"},{"key":"10134_CR14","unstructured":"(NCCIH) NCfCaIH. Complementary, alternative, or integrative health: what\u2019s in a name? 2025."},{"key":"10134_CR15","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s10620-014-3498-3","volume":"60","author":"A Hung","year":"2015","unstructured":"Hung A, Kang N, Bollom A, Wolf JL, Lembo A. Complementary and alternative medicine use is prevalent among patients with gastrointestinal diseases. Dig Dis Sci 2015;60:1883\u20131888. https:\/\/doi.org\/10.1007\/s10620-014-3498-3.","journal-title":"Dig Dis Sci"},{"key":"10134_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/medicina55020046","volume":"55","author":"T Larussa","year":"2019","unstructured":"Larussa T, Rossi M, Suraci E et al. Use of complementary and alternative medicine by patients with irritable bowel syndrome according to the roma IV criteria: a single-center italian survey. Medicina (Kaunas) 2019;55:46.","journal-title":"Medicina (Kaunas)"},{"key":"10134_CR17","first-page":"1948","volume":"65","author":"LQ Bian","year":"2024","unstructured":"Bian LQ, Huang SG, Wei W, Wen Y, Tang X. Expert consensus on diagnosis and treatment of irritable bowel syndrome with traditional Chinese medicine (2024). J Tradit Chin Med 2024;65:1948\u20131956.","journal-title":"J Tradit Chin Med"},{"key":"10134_CR18","doi-asserted-by":"publisher","first-page":"118256","DOI":"10.1016\/j.jep.2024.118256","volume":"331","author":"F Jia","year":"2024","unstructured":"Jia F, Du L, He J et al. Tong-Xie-Yao-Fang strengthens intestinal feedback control of bile acid synthesis to ameliorate irritable bowel syndrome by enhancing bile salt hydrolase-expressing microbiota. J Ethnopharmacol 2024;331:118256.","journal-title":"J Ethnopharmacol"},{"key":"10134_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3389\/fphar.2018.01110","volume":"9","author":"J Li","year":"2018","unstructured":"Li J, Cui H, Cai Y et al. Tong-Xie-Yao-Fang regulates 5-HT level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation. Front Pharmacol 2018;9:1110.","journal-title":"Front Pharmacol"},{"key":"10134_CR20","doi-asserted-by":"publisher","first-page":"6679348","DOI":"10.1155\/2021\/6679348","volume":"2021","author":"X Tan","year":"2021","unstructured":"Tan X, Pei W, Xie C et al. Tongxie anchang decoction relieves visceral hypersensitivity in diarrhea-predominant irritable bowel syndrome rats by regulating the NGF\/TrkA signaling pathway. Evid Based Complement Alternat Med 2021;2021:6679348.","journal-title":"Evid Based Complement Alternat Med"},{"key":"10134_CR21","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.3748\/wjg.v21.i15.4536","volume":"21","author":"Y Yin","year":"2015","unstructured":"Yin Y, Zhong L, Wang JW, Zhao XY, Zhao WJ, Kuang HX. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J Gastroenterol 2015;21:4536\u20134546.","journal-title":"World J Gastroenterol"},{"key":"10134_CR22","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2147\/DDDT.S423333","volume":"17","author":"X Lu","year":"2023","unstructured":"Lu X, Zhang S. How tongxie-yaofang regulates intestinal synaptic plasticity by activating enteric glial cells and NGF\/TrkA pathway in diarrhea-predominant irritable bowel syndrome rats. Drug Des Devel Ther 2023;17:2969\u20132983.","journal-title":"Drug Des Devel Ther"},{"key":"10134_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12906-019-2749-4","volume":"19","author":"Q Hou","year":"2019","unstructured":"Hou Q, Huang Y, Zhu Z et al. Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-\u03baB and notch signalling pathways. BMC Complement Altern Med 2019;19:337.","journal-title":"BMC Complement Altern Med"},{"key":"10134_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.62347\/VZJL1218","volume":"16","author":"XY Han","year":"2024","unstructured":"Han XY, Song XG, Ma WL et al. Electroacupuncture protects the intestinal mucosal barrier in diarrhea-predominant Irritable Bowel Syndrome rats by regulating the MCs\/Tryptase\/PAR-2\/MLCK pathway. Am J Transl Res 2024;16:781\u2013793.","journal-title":"Am J Transl Res"},{"key":"10134_CR25","first-page":"494","volume":"43","author":"S Mengzhu","year":"2023","unstructured":"Mengzhu S, Yujie Z, Yafang S et al. Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines. J Tradit Chin Med 2023;43:494\u2013500.","journal-title":"J Tradit Chin Med"},{"key":"10134_CR26","doi-asserted-by":"publisher","first-page":"3904571","DOI":"10.1155\/2022\/3904571","volume":"2022","author":"S He","year":"2022","unstructured":"He S, Lin Q, Huang J, Zheng L, Lai J, Chen C. Effect and mechanism of flavored tongxie yaofang decoction for diarrheal irritable bowel syndrome under intestinal microecology. Evid Based Complement Alternat Med 2022;2022:3904571.","journal-title":"Evid Based Complement Alternat Med"},{"key":"10134_CR27","doi-asserted-by":"publisher","first-page":"e088410","DOI":"10.1136\/bmjopen-2024-088410","volume":"15","author":"SB Liang","year":"2025","unstructured":"Liang SB, Cheng HJ, Zhang QY et al. Chinese herbal formula Tongxie Yaofang granules for diarrhoea-predominant irritable bowel syndrome: a randomised, double-blind, placebo-controlled, phase II trial. BMJ Open 2025;15:e088410.","journal-title":"BMJ Open"},{"key":"10134_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102839","volume":"68","author":"Y Lai","year":"2022","unstructured":"Lai Y, Liang X, Fan H et al. Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: a randomized controlled trial. Complement Ther Med 2022;68:102839.","journal-title":"Complement Ther Med"},{"key":"10134_CR29","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"National Pharmacopoeia Commission","year":"2020","unstructured":"National Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China. China Medical Science and Technology Press; 2020."},{"key":"10134_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","volume":"163","author":"A Lembo","year":"2022","unstructured":"Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology 2022;163:137\u2013151.","journal-title":"Gastroenterology"},{"key":"10134_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13030-024-00302-y","volume":"18","author":"K Matsueda","year":"2024","unstructured":"Matsueda K, Fukudo S, Ogishima M, Naito Y, Nakamura S. Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study. Biopsychosoc Med 2024;18:3.","journal-title":"Biopsychosoc Med"},{"key":"10134_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s10620-015-3858-7","volume":"61","author":"BD Cash","year":"2016","unstructured":"Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci 2016;61:560\u2013571. https:\/\/doi.org\/10.1007\/s10620-015-3858-7.","journal-title":"Dig Dis Sci"},{"key":"10134_CR33","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.14309\/ajg.0000000000001395","volume":"116","author":"J Nee","year":"2021","unstructured":"Nee J, Ballou S, Kelley JM et al. peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial. Am J Gastroenterol 2021;116:2279\u20132285.","journal-title":"Am J Gastroenterol"},{"key":"10134_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.gastro.2019.08.026","volume":"158","author":"Z Weerts","year":"2020","unstructured":"Weerts Z, Masclee AAM, Witteman BJM et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020;158:123\u2013136.","journal-title":"Gastroenterology"},{"key":"10134_CR35","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.3390\/microorganisms12102036","volume":"12","author":"P Pastras","year":"2024","unstructured":"Pastras P, Aggeletopoulou I, Triantos C. Impact of enteric nervous cells on irritable bowel syndrome: potential treatment options. Microorganisms 2024;12:2036.","journal-title":"Microorganisms"},{"key":"10134_CR36","doi-asserted-by":"publisher","first-page":"8186106","DOI":"10.1155\/2020\/8186106","volume":"2020","author":"F Zhang","year":"2020","unstructured":"Zhang F, Ma Z, Weng Z et al. P2X(3) receptor in primary afferent neurons mediates the relief of visceral hypersensitivity by electroacupuncture in an irritable bowel syndrome rat model. Gastroenterol Res Pract 2020;2020:8186106.","journal-title":"Gastroenterol Res Pract"},{"key":"10134_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11302-015-9447-6","volume":"11","author":"ZJ Weng","year":"2015","unstructured":"Weng ZJ, Wu LY, Zhou CL et al. Effect of electroacupuncture on P2X3 receptor regulation in the peripheral and central nervous systems of rats with visceral pain caused by irritable bowel syndrome. Purinergic Signal 2015;11:321\u2013329.","journal-title":"Purinergic Signal"},{"key":"10134_CR38","first-page":"5563","volume":"14","author":"HY Tang","year":"2022","unstructured":"Tang HY, Chen XQ, Wang H et al. Acupuncture relieves the visceral pain of diarrhea-predominant irritable bowel syndrome rats by regulating P2X4 expression. Am J Transl Res 2022;14:5563\u20135573.","journal-title":"Am J Transl Res"},{"key":"10134_CR39","first-page":"981","volume":"44","author":"Z Fang","year":"2024","unstructured":"Fang Z, Cuina Y, Zhijun W et al. Regulatory role of electroacupuncture on satellite glial cell activity in the colon and dorsal root ganglion of rats with irritable bowel syndrome. J Tradit Chin Med 2024;44:981\u2013990.","journal-title":"J Tradit Chin Med"},{"key":"10134_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2021.736512","volume":"15","author":"T Zhao","year":"2021","unstructured":"Zhao T, Pei L, Ning H et al. Networks are associated with acupuncture treatment in patients with diarrhea-predominant irritable bowel syndrome: a resting-state imaging study. Front Hum Neurosci 2021;15:736512.","journal-title":"Front Hum Neurosci"},{"key":"10134_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.608688","volume":"14","author":"K Ma","year":"2020","unstructured":"Ma K, Liu Y, Shao W et al. Brain functional interaction of acupuncture effects in diarrhea-dominant irritable bowel syndrome. Front Neurosci 2020;14:608688.","journal-title":"Front Neurosci"},{"key":"10134_CR42","doi-asserted-by":"publisher","first-page":"1383041","DOI":"10.3389\/fnins.2024.1383041","volume":"18","author":"J Li","year":"2024","unstructured":"Li J, Ng W, Liu Y et al. Neuroplasticity of the white matter tracts underlying recovery of diarrhea-predominant irritable bowel syndrome following acupuncture treatment. Front Neurosci 2024;18:1383041.","journal-title":"Front Neurosci"},{"key":"10134_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neulet.2009.09.018","volume":"465","author":"HG Wu","year":"2009","unstructured":"Wu HG, Liu HR, Zhang ZA et al. Electro-acupuncture relieves visceral sensitivity and decreases hypothalamic corticotropin-releasing hormone levels in a rat model of irritable bowel syndrome. Neurosci Lett 2009;465:235\u2013237.","journal-title":"Neurosci Lett"},{"key":"10134_CR44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1152\/jn.00156.2023","volume":"130","author":"F Gao","year":"2023","unstructured":"Gao F, Yuan WH, Wu SB, Wang ZB, Zhu GQ, Zhou MQ. Electroacupuncture in the treatment of IBS in rats: investigation of the mechanisms of CRH(+) neurons in the paraventricular nucleus. J Neurophysiol 2023;130:380\u2013391.","journal-title":"J Neurophysiol"},{"key":"10134_CR45","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.3748\/wjg.15.5211","volume":"15","author":"XP Ma","year":"2009","unstructured":"Ma XP, Tan LY, Yang Y et al. Effect of electro-acupuncture on substance P, its receptor and corticotropin-releasing hormone in rats with irritable bowel syndrome. World J Gastroenterol 2009;15:5211\u20135217.","journal-title":"World J Gastroenterol"},{"key":"10134_CR46","doi-asserted-by":"publisher","first-page":"2562979","DOI":"10.1155\/2020\/2562979","volume":"2020","author":"M Zhao","year":"2020","unstructured":"Zhao M, Wang Z, Weng Z et al. Electroacupuncture improves IBS visceral hypersensitivity by inhibiting the activation of astrocytes in the medial thalamus and anterior cingulate cortex. Evid Based Complement Alternat Med 2020;2020:2562979.","journal-title":"Evid Based Complement Alternat Med"},{"key":"10134_CR47","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3390\/nu13072469","volume":"13","author":"L Prospero","year":"2021","unstructured":"Prospero L, Riezzo G, Linsalata M, Orlando A, D\u2019Attoma B, Russo F. Psychological and gastrointestinal symptoms of patients with irritable bowel syndrome undergoing a low-FODMAP diet: the role of the intestinal barrier. Nutrients 2021;13:2469.","journal-title":"Nutrients"},{"key":"10134_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.917579","volume":"13","author":"Y Hou","year":"2022","unstructured":"Hou Y, Zhao Y, Jiang H et al. Maintenance of intestinal homeostasis in diarrhea-predominant irritable bowel syndrome by electroacupuncture through submucosal enteric glial cell-derived s-nitrosoglutathione. Front Physiol 2022;13:917579.","journal-title":"Front Physiol"},{"key":"10134_CR49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13020-018-0220-y","volume":"13","author":"X Wang","year":"2018","unstructured":"Wang X, Qi Q, Wang Y et al. Gut microbiota was modulated by moxibustion stimulation in rats with irritable bowel syndrome. Chin Med 2018;13:63.","journal-title":"Chin Med"},{"key":"10134_CR50","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s11684-024-1073-7","volume":"18","author":"J Zhao","year":"2024","unstructured":"Zhao J, Zheng H, Wang X et al. Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial. Front Med 2024;18:678\u2013689.","journal-title":"Front Med"},{"key":"10134_CR51","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.mayocp.2020.01.042","volume":"95","author":"L Pei","year":"2020","unstructured":"Pei L, Geng H, Guo J et al. Effect of acupuncture in patients with irritable bowel syndrome: a randomized controlled trial. Mayo Clin Proc 2020;95:1671\u20131683.","journal-title":"Mayo Clin Proc"},{"key":"10134_CR52","doi-asserted-by":"publisher","first-page":"e2248817","DOI":"10.1001\/jamanetworkopen.2022.48817","volume":"5","author":"LY Qi","year":"2022","unstructured":"Qi LY, Yang JW, Yan SY et al. Acupuncture for the treatment of diarrhea-predominant irritable bowel syndrome: a pilot randomized clinical trial. JAMA Netw Open 2022;5:e2248817.","journal-title":"JAMA Netw Open"},{"key":"10134_CR53","doi-asserted-by":"publisher","first-page":"115064","DOI":"10.1016\/j.jep.2022.115064","volume":"289","author":"Z Wang","year":"2022","unstructured":"Wang Z, Xu M, Shi Z et al. Mild moxibustion for irritable bowel syndrome with diarrhea (IBS-D): a randomized controlled trial. J Ethnopharmacol. 2022;289:115064.","journal-title":"J Ethnopharmacol."},{"key":"10134_CR54","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.neurom.2021.10.009","volume":"25","author":"P Hu","year":"2022","unstructured":"Hu P, Sun K, Li H et al. Transcutaneous electrical acustimulation improved the quality of life in patients with diarrhea-irritable bowel syndrome. Neuromodulation 2022;25:1165\u20131172.","journal-title":"Neuromodulation"},{"key":"10134_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100721","volume":"99","author":"GM Ahlawat","year":"2023","unstructured":"Ahlawat GM, Singh PK. Methods of determining irritable bowel syndrome and efficiency of probiotics in treatment: a review. Curr Ther Res Clin Exp 2023;99:100721.","journal-title":"Curr Ther Res Clin Exp"},{"key":"10134_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2021;116:17\u201344.","journal-title":"Am J Gastroenterol"},{"key":"10134_CR57","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/jcag\/gwy071","volume":"2","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Andrews CN, MacQueen G et al. Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). J Can Assoc Gastroenterol 2019;2:6\u201329.","journal-title":"J Can Assoc Gastroenterol"},{"key":"10134_CR58","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.cgh.2024.04.021","volume":"23","author":"P Singh","year":"2025","unstructured":"Singh P, Chey SW, Nee J, Eswaran S, Lembo A, Chey WD. Is a simplified, less restrictive low FODMAP diet possible? Results from a double-blind, pilot randomized controlled trial. Clin Gastroenterol Hepatol 2025;23:362-364.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10134_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","volume":"146","author":"EP Halmos","year":"2014","unstructured":"Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75.e5.","journal-title":"Gastroenterology"},{"key":"10134_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1172\/JCI92390","volume":"128","author":"SY Zhou","year":"2018","unstructured":"Zhou SY, Gillilland M 3rd, Wu X et al. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J Clin Invest 2018;128:267\u2013280.","journal-title":"J Clin Invest"},{"key":"10134_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000448280","volume":"94","author":"J Valeur","year":"2016","unstructured":"Valeur J, R\u00f8seth AG, Knudsen T et al. Fecal fermentation in irritable bowel syndrome: influence of dietary restriction of fermentable oligosaccharides, disaccharides monosaccharides and polyols. Digestion 2016;94:50\u201356.","journal-title":"Digestion"},{"key":"10134_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12969","author":"TN Hustoft","year":"2017","unstructured":"Hustoft TN, Hausken T, Ystad SO et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017. https:\/\/doi.org\/10.1111\/nmo.12969.","journal-title":"Neurogastroenterol Motil"},{"key":"10134_CR63","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1016\/j.clnu.2020.12.041","volume":"40","author":"A Eetemadi","year":"2021","unstructured":"Eetemadi A, Tagkopoulos I. Methane and fatty acid metabolism pathways are predictive of Low-FODMAP diet efficacy for patients with irritable bowel syndrome. Clin Nutr. 2021;40:4414\u20134421.","journal-title":"Clin Nutr."},{"key":"10134_CR64","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.3390\/nu14214628","volume":"14","author":"GR Caponio","year":"2022","unstructured":"Caponio GR, Celano G, Calabrese FM et al. Evaluation of the effects of the tritordeum-based diet compared to the low-FODMAPs diet on the fecal metabolome of IBS-D patients: a preliminary investigation. Nutrients 2022;14:4628.","journal-title":"Nutrients"},{"key":"10134_CR65","doi-asserted-by":"publisher","first-page":"R248","DOI":"10.1152\/ajpregu.00016.2023","volume":"325","author":"E Nordin","year":"2023","unstructured":"Nordin E, Hellstr\u00f6m PM, Vuong E, Ribbenstedt A, Brunius C, Landberg R. IBS randomized study: FODMAPs alter bile acids, phenolic- and tryptophan metabolites, while gluten modifies lipids. Am J Physiol Regul Integr Comp Physiol 2023;325:R248\u2013R259.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10134_CR66","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1136\/gutjnl-2021-325821","volume":"71","author":"F Carbone","year":"2022","unstructured":"Carbone F, Van den Houte K, Besard L et al. Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute. Gut 2022;71:2226\u20132232.","journal-title":"Gut"},{"key":"10134_CR67","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2468-1253(24)00045-1","volume":"9","author":"S Nybacka","year":"2024","unstructured":"Nybacka S, T\u00f6rnblom H, Josefsson A et al. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. Lancet Gastroenterol Hepatol 2024;9:507\u2013520.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10134_CR68","doi-asserted-by":"publisher","first-page":"947","DOI":"10.14309\/ajg.0000000000001767","volume":"117","author":"P Singh","year":"2022","unstructured":"Singh P, Tuck C, Gibson PR, Chey WD. The role of food in the treatment of bowel disorders: focus on irritable bowel syndrome and functional constipation. Am J Gastroenterol 2022;117:947\u2013957.","journal-title":"Am J Gastroenterol"},{"key":"10134_CR69","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/apt.15419","volume":"50","author":"XJ Wang","year":"2019","unstructured":"Wang XJ, Camilleri M, Vanner S, Tuck C. Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to dietary restriction. Aliment Pharmacol Ther 2019;50:517\u2013529.","journal-title":"Aliment Pharmacol Ther"},{"key":"10134_CR70","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cgh.2024.03.047","volume":"23","author":"S Eswaran","year":"2025","unstructured":"Eswaran S, Jencks KJ, Singh P, Rifkin S, Han-Markey T, Chey WD. All FODMAPs aren\u2019t created equal: results of a randomized reintroduction trial in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2025;23:351-358.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10134_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1053\/j.gastro.2024.02.008","volume":"167","author":"K Van den Houte","year":"2024","unstructured":"Van den Houte K, Colomier E, Routhiaux K et al. Efficacy and findings of a blinded randomized reintroduction phase for the low FODMAP diet in irritable bowel syndrome. Gastroenterology 2024;167:333\u2013342.","journal-title":"Gastroenterology"},{"key":"10134_CR72","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.3390\/nu16173039","volume":"16","author":"B Roth","year":"2024","unstructured":"Roth B, Nseir M, Jeppsson H, D\u2019Amato M, Sundquist K, Ohlsson B. A starch- and sucrose-reduced diet has similar efficiency as low FODMAP in IBS-A randomized non-inferiority study. Nutrients 2024;16:3039.","journal-title":"Nutrients"},{"key":"10134_CR73","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.17791","volume":"59","author":"HM Staudacher","year":"2024","unstructured":"Staudacher HM, Mahoney S, Canale K et al. Clinical trial: a Mediterranean diet is feasible and improves gastrointestinal and psychological symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2024;59:492\u2013503.","journal-title":"Aliment Pharmacol Ther"},{"key":"10134_CR74","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/gutjnl-2021-325177","volume":"71","author":"K Vervier","year":"2022","unstructured":"Vervier K, Moss S, Kumar N et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut 2022;71:1821\u20131830.","journal-title":"Gut"},{"key":"10134_CR75","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1039\/D0FO03162C","volume":"12","author":"F Valdez-Palomares","year":"2021","unstructured":"Valdez-Palomares F, Nambo-Venegas R, Uribe-Garc\u00eda J et al. Intestinal microbiota fingerprint in subjects with irritable bowel syndrome responders to a low FODMAP diet. Food Funct 2021;12:3206\u20133218.","journal-title":"Food Funct"},{"key":"10134_CR76","doi-asserted-by":"publisher","first-page":"175628482210751","DOI":"10.1177\/17562848221075131","volume":"15","author":"C Bao","year":"2022","unstructured":"Bao C, Wu L, Shi Y et al. Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial. Therap Adv Gastroenterol 2022;15:17562848221075132.","journal-title":"Therap Adv Gastroenterol"},{"key":"10134_CR77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/09645284211027892","volume":"40","author":"J Guo","year":"2022","unstructured":"Guo J, Lu G, Chen L et al. Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome. Acupunct Med 2022;40:34\u201342.","journal-title":"Acupunct Med"},{"key":"10134_CR78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11306-023-02083-x","volume":"20","author":"E Nordin","year":"2024","unstructured":"Nordin E, Landberg R, Hellstr\u00f6m PM, Brunius C. Exploration of differential responses to FODMAPs and gluten in people with irritable bowel syndrome- a double-blind randomized cross-over challenge study. Metabolomics 2024;20:21.","journal-title":"Metabolomics"},{"key":"10134_CR79","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/ajcn\/nqab337","volume":"115","author":"E Nordin","year":"2022","unstructured":"Nordin E, Brunius C, Landberg R, Hellstr\u00f6m PM. Fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs), but not gluten, elicit modest symptoms of irritable bowel syndrome: a double-blind, placebo-controlled, randomized three-way crossover trial. Am J Clin Nutr 2022;115:344\u2013352.","journal-title":"Am J Clin Nutr"},{"key":"10134_CR80","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3390\/nu15133045","volume":"15","author":"E Nordin","year":"2023","unstructured":"Nordin E, Hellstr\u00f6m PM, Dicksved J, Pelve E, Landberg R, Brunius C. Effects of FODMAPs and gluten on gut microbiota and their association with the metabolome in irritable bowel syndrome: a double-blind, randomized, cross-over intervention study. Nutrients 2023;15:3045.","journal-title":"Nutrients"},{"key":"10134_CR81","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3390\/nu15081837","volume":"15","author":"C Chojnacki","year":"2023","unstructured":"Chojnacki C, Poplawski T, Blonska A, Konrad P, Chojnacki J, Blasiak J. The usefulness of the low-FODMAP diet with limited tryptophan intake in the treatment of diarrhea-predominant irritable bowel syndrome. Nutrients 2023;15:1837.","journal-title":"Nutrients"},{"key":"10134_CR82","doi-asserted-by":"publisher","first-page":"906","DOI":"10.14309\/ajg.0000000000000641","volume":"115","author":"B Wilson","year":"2020","unstructured":"Wilson B, Rossi M, Kanno T et al. \u03b2-galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal bifidobacteria. Am J Gastroenterol 2020;115:906\u2013915.","journal-title":"Am J Gastroenterol"},{"key":"10134_CR83","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ajcn\/nqab005","volume":"113","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Feng L, Wang X et al. Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes. Am J Clin Nutr 2021;113:1531\u20131545.","journal-title":"Am J Clin Nutr"},{"key":"10134_CR84","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.clnu.2022.11.001","volume":"41","author":"JP Algera","year":"2022","unstructured":"Algera JP, Demir D, T\u00f6rnblom H, Nybacka S, Simr\u00e9n M, St\u00f6rsrud S. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: a randomized crossover trial. Clin Nutr 2022;41:2792\u20132800.","journal-title":"Clin Nutr"},{"key":"10134_CR85","doi-asserted-by":"publisher","first-page":"e30291","DOI":"10.2196\/30291","volume":"23","author":"DV Ankersen","year":"2021","unstructured":"Ankersen DV, Weimers P, Bennedsen M et al. Long-term effects of a web-based low-FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double-crossover clinical trial. J Med Internet Res 2021;23:e30291.","journal-title":"J Med Internet Res"},{"key":"10134_CR86","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/jcm9010125","volume":"9","author":"MM Guerreiro","year":"2020","unstructured":"Guerreiro MM, Santos Z, Carolino E et al. Effectiveness of two dietary approaches on the quality of life and gastrointestinal symptoms of individuals with irritable bowel syndrome. J Clin Med 2020;9:125.","journal-title":"J Clin Med"},{"key":"10134_CR87","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1053\/j.gastro.2024.11.003","volume":"168","author":"KW Hung","year":"2025","unstructured":"Hung KW, Leiman DA, Kaza A, Watson R, Chang L, Maratt JK. AGA institute quality indicator development for irritable bowel syndrome. Gastroenterology 2025;168:612-622.e4.","journal-title":"Gastroenterology"},{"key":"10134_CR88","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.cgh.2020.09.035","volume":"19","author":"W Billings","year":"2021","unstructured":"Billings W, Mathur K, Craven HJ, Xu H, Shin A. Potential benefit with complementary and alternative medicine in irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19:1538-1553.e14.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10134_CR89","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13020-021-00530-2","volume":"16","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Ching J, Cheng CW et al. Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial. Chin Med 2021;16:117.","journal-title":"Chin Med"},{"key":"10134_CR90","doi-asserted-by":"publisher","first-page":"111889","DOI":"10.1016\/j.jep.2019.111889","volume":"238","author":"YS Shih","year":"2019","unstructured":"Shih YS, Tsai CH, Li TC et al. The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Ethnopharmacol 2019;238:111889.","journal-title":"J Ethnopharmacol"},{"key":"10134_CR91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000485410","volume":"35","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig Dis 2017;35:25\u201329.","journal-title":"Dig Dis"},{"key":"10134_CR92","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5056\/jnm19041","volume":"25","author":"KA Gwee","year":"2019","unstructured":"Gwee KA, Gonlachanvit S, Ghoshal UC et al. Second Asian consensus on irritable bowel syndrome. J Neurogastroenterol Motil 2019;25:343\u2013362.","journal-title":"J Neurogastroenterol Motil"},{"key":"10134_CR93","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.3748\/wjg.v25.i34.5134","volume":"25","author":"XY Zhao","year":"2019","unstructured":"Zhao XY, Wang JW, Yin Y, Li K, Zhang M, Yan FP. Effect of Tong Xie Yao Fang on endogenous metabolites in urine of irritable bowel syndrome model rats. World J Gastroenterol 2019;25:5134\u20135151.","journal-title":"World J Gastroenterol"},{"key":"10134_CR94","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.14309\/ajg.0000000000002862","volume":"119","author":"V Tunali","year":"2024","unstructured":"Tunali V, Arslan N, Ermi\u015f BH et al. A multicenter randomized controlled trial of microbiome-based artificial intelligence-assisted personalized diet vs low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet: a novel approach for the management of irritable bowel syndrome. Am J Gastroenterol 2024;119:1901\u20131912.","journal-title":"Am J Gastroenterol"},{"key":"10134_CR95","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/diagnostics13213336","volume":"13","author":"RA Vulpoi","year":"2023","unstructured":"Vulpoi RA, Luca M, Ciobanu A et al. The potential use of artificial intelligence in irritable bowel syndrome management. Diagnostics (Basel) 2023;13:3336.","journal-title":"Diagnostics (Basel)"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10134-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10134-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10134-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:02:30Z","timestamp":1789628550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10134-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10134"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10134-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}